NO943524L - Fremgangsmåte for behandling av tumor - Google Patents

Fremgangsmåte for behandling av tumor

Info

Publication number
NO943524L
NO943524L NO943524A NO943524A NO943524L NO 943524 L NO943524 L NO 943524L NO 943524 A NO943524 A NO 943524A NO 943524 A NO943524 A NO 943524A NO 943524 L NO943524 L NO 943524L
Authority
NO
Norway
Prior art keywords
treatment
administering
tumor
tumors
mammal
Prior art date
Application number
NO943524A
Other languages
English (en)
Norwegian (no)
Other versions
NO943524D0 (no
Inventor
Martin J Brown
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of NO943524D0 publication Critical patent/NO943524D0/no
Publication of NO943524L publication Critical patent/NO943524L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO943524A 1993-09-22 1994-09-22 Fremgangsmåte for behandling av tumor NO943524L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/125,609 US5484612A (en) 1993-09-22 1993-09-22 Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin

Publications (2)

Publication Number Publication Date
NO943524D0 NO943524D0 (no) 1994-09-22
NO943524L true NO943524L (no) 1995-03-23

Family

ID=22420569

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943524A NO943524L (no) 1993-09-22 1994-09-22 Fremgangsmåte for behandling av tumor

Country Status (22)

Country Link
US (4) US5484612A (de)
EP (2) EP0972517B1 (de)
JP (1) JPH07215882A (de)
KR (1) KR100383402B1 (de)
AT (2) ATE193827T1 (de)
AU (1) AU690132B2 (de)
CA (1) CA2132578C (de)
CZ (1) CZ289742B6 (de)
DE (2) DE69433889T2 (de)
DK (2) DK0649658T3 (de)
ES (2) ES2224517T3 (de)
GR (1) GR3034360T3 (de)
HU (1) HUT71119A (de)
IL (1) IL111025A (de)
MY (1) MY112405A (de)
NO (1) NO943524L (de)
NZ (2) NZ299690A (de)
PT (2) PT649658E (de)
RU (1) RU2148406C1 (de)
SG (1) SG52568A1 (de)
SK (1) SK282178B6 (de)
UA (1) UA49787C2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
US5672702A (en) * 1995-12-04 1997-09-30 Sanofi Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide
EP1014990B1 (de) * 1997-03-07 2006-09-06 Sanofi-Aventis U.S. LLC Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
DE69841058D1 (de) * 1997-11-14 2009-09-24 Gen Hospital Corp Behandlung von hämatologischen störungen
US6074626A (en) * 1998-03-20 2000-06-13 Molecular Radiation Management, Inc. Radioactive cisplatin in the treatment of cancer
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6819761B1 (en) * 1999-09-16 2004-11-16 Silicon Laboratories, Inc. Programmable constant current “off hook” circuit
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
WO2001046162A2 (de) 1999-12-21 2001-06-28 Ufz Umweltforschungszentrum Leipzig-Halle Gmbh Neue 3-substituierte 1,2,4-benzotriazine, verfahren zu ihrer herstellung und ihre verwendung zur behandlung und prophylaxe von tumorerkrankungen
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
RU2166945C1 (ru) * 2000-08-08 2001-05-20 Ефимова Лариса Степановна Радиосенсибилизирующее вещество для лечения онкологических заболеваний
US6586460B1 (en) 2001-04-02 2003-07-01 The Board Of Regents For Oklahoma State University Heteroarotinoids containing urea or thiourea linker
RU2192862C1 (ru) * 2001-05-23 2002-11-20 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения больших и мультицентричных ретинобластом
AT412703B (de) 2001-12-04 2005-06-27 Vis Vitalis Lizenz & Handels Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
NZ521436A (en) * 2002-09-17 2005-07-29 Auckland Uniservices Ltd DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
RU2234916C2 (ru) * 2002-10-29 2004-08-27 Московский областной научно-исследовательский клинический институт Способ лечения онкологических больных
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
CA2456569A1 (en) * 2003-03-14 2004-09-14 Auckland Uniservices Limited Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
RU2243766C1 (ru) * 2003-04-01 2005-01-10 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рецидивов рака шейки матки
US7816521B2 (en) 2004-03-01 2010-10-19 Auckland Uniservices Limited 1,2,4-benzotriazine-1,4-dioxides
EP1866292B1 (de) * 2005-03-31 2010-12-15 Auckland Uniservices Limited Tricylische 1,2,4-triazinoxide und zusammensetzungen davon zur therapeutischen anwendung bei krebsbehandlungen
JP2009510165A (ja) * 2005-10-03 2009-03-12 ジェネティックス ファーマシューティカルズ， インク． 低酸素細胞を選択的に枯渇させるための方法
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
ES2395401T3 (es) * 2006-03-23 2013-02-12 Tmrc Co., Ltd. kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer
AU2009209515A1 (en) * 2008-01-28 2009-08-06 Milux Holding Sa Blood clot removal device, system, and method
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
US9316632B2 (en) * 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
AT511159A1 (de) 2011-02-16 2012-09-15 Selo Medical Gmbh Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen
EP2800744A4 (de) * 2011-12-07 2015-06-03 Sri Internat Inc Benzotriazinoxide als arzneimittel gegen mycobacterium tuberculosis
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US10947196B2 (en) 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
EP3993878A4 (de) * 2019-07-01 2023-11-08 Curasen Therapeutics, Inc. Beta-adrenerger agonist und verfahren zu seiner verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US4923878A (en) * 1988-11-14 1990-05-08 Merck & Co., Inc. Quinolizine sulfonamides used against certain neoplastic disease states
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides

Also Published As

Publication number Publication date
SK114894A3 (en) 1995-11-08
US6277835B1 (en) 2001-08-21
CA2132578C (en) 1998-10-13
DE69433889T2 (de) 2005-06-30
IL111025A (en) 2006-04-10
KR950007853A (ko) 1995-04-15
RU94034104A (ru) 1996-11-10
IL111025A0 (en) 1994-11-28
EP0649658B1 (de) 2000-06-14
ES2224517T3 (es) 2005-03-01
HUT71119A (en) 1995-11-28
DE69424915D1 (de) 2000-07-20
NZ299690A (en) 1997-11-24
AU690132B2 (en) 1998-04-23
CZ232694A3 (en) 1995-09-13
PT972517E (pt) 2004-11-30
DE69433889D1 (de) 2004-08-12
NO943524D0 (no) 1994-09-22
DK0649658T3 (da) 2000-09-11
EP0649658A1 (de) 1995-04-26
ATE193827T1 (de) 2000-06-15
ATE270553T1 (de) 2004-07-15
UA49787C2 (uk) 2002-10-15
AU7411794A (en) 1995-04-06
US5484612A (en) 1996-01-16
RU2148406C1 (ru) 2000-05-10
GR3034360T3 (en) 2000-12-29
EP0972517B1 (de) 2004-07-07
CA2132578A1 (en) 1995-03-23
SG52568A1 (en) 1998-09-28
JPH07215882A (ja) 1995-08-15
SK282178B6 (sk) 2001-11-06
ES2147567T3 (es) 2000-09-16
DK0972517T3 (da) 2004-11-08
PT649658E (pt) 2000-12-29
KR100383402B1 (ko) 2003-09-22
CZ289742B6 (cs) 2002-03-13
US6121263A (en) 2000-09-19
NZ264502A (en) 1997-06-24
MY112405A (en) 2001-06-30
HU9402726D0 (en) 1994-12-28
DE69424915T2 (de) 2001-01-18
EP0972517A3 (de) 2000-01-26
EP0972517A2 (de) 2000-01-19
US5670502A (en) 1997-09-23

Similar Documents

Publication Publication Date Title
NO943524D0 (no) Fremgangsmåte for behandling av tumor
NZ280667A (en) Use of estrogen agonists for treating prostatic disease, bone loss or obesity
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
PT734259E (pt) Utilizacao de derivados de piperidina para o tratamento da esquizofrenia
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
NO891703D0 (no) Farmasoeytiske sammensetninger for behandling av psoriasis.
PT76782A (en) Process for preparing novel substituted (+)-cyanidan-3-ol derivatives
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
IL112963A0 (en) A pharmaceutical composition containing gamma globulins or fragments thereof
DE69822626D1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
NO923198L (no) Terapeutiske midler
ATE100439T1 (de) 2-(2-hydroxy-3-phenoxypropylamino)-ethoxybenzol derivate.
ES2040750T3 (es) Un procedimiento para la preparacion de un derivado de isoquinolinol.